Asciminib monthly cost and reference price after medical insurance reimbursement

Asciminib (Asciminib, also known as Asciminib) is a new type of ABL inhibitor agent, mainly used to treat patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to previous TKI therapies. As an innovative targeted drug approved for marketing in recent years, its unique "chimeric pocket" mechanism of action allows many drug-resistant patients to regain treatment opportunities. As the drug is launched in China, more and more patients are beginning to pay attention to its actual monthly medication cost and whether it is expected to be included in the medical insurance reimbursement system in the future.

At present, Acemini has been approved for marketing in China, but it has not yet been included in the national medical insurance directory, so patients need to purchase it at their own expense. The specific selling price shall be subject to the announcement by the hospital pharmacies in various places. Based on clinically recommended dosages (usually taken daily), one patient's monthly dosage is roughly equivalent to one box of medication. Due to the high price of original drugs, the actual monthly drug expenditure may cost tens of thousands of yuan, which is a considerable financial burden for chronic leukemia patients who have been taking drugs for a long time.

In overseas markets, Asnib has two main sources: the European version of the original drug and the Laotian generic drug. The European version of the original drug is more expensive, with a box costing around tens of thousands of yuan, and the cost of long-term treatment is even higher. The Lao version of generic drugs provides a more cost-effective option. The price per box is about more than 4,000 yuan. The drug ingredients are basically the same as the original drugs. It is a feasible alternative for patients who cannot afford the high cost of original drugs.

Currently, Asnib is not included in the medical insurance catalog, and patients need to pay the full amount out of their own pocket. If it is included in medical insurance in the future, and through price reduction and medical insurance reimbursement policies negotiated by the state, the patient's out-of-pocket payment ratio is expected to be significantly reduced, and the actual monthly expenditure may be reduced to a few thousand yuan or even lower. As the drug is increasingly used clinically, the advancement of medical insurance coverage is expected to significantly alleviate patients' financial pressure, improve the accessibility of the drug, and bring hope for long-term treatment to more CML patients.

Reference materials:https://www.drugs.com/